GlassScriptPhysician profile
Caedran Peete
NPI 1811413842
$1,817.69
in general payments reported to CMS, 2019-2025
21 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $771 · 2022: $474 · 2023: $335 · 2024: $126 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $305.15 | 2021-2024 | |
| Lilly USA, LLC | $224.99 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $218.70 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $160.18 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $158.25 | 2021-2022 | |
| Amgen INC. | $129.63 | 2021-2022 | |
| Genzyme Corporation | $122.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $101.26 | 2023 | |
| Arcutis Biotherapeutics, INC. | $81.65 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $52.78 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $47.38 | 2021-2022 | |
| Ucb, INC. | $36.61 | 2025 | Bimzelx |
| Pfizer INC. | $29.29 | 2021 | |
| Vyne Pharmaceuticals INC. | $29.16 | 2021 | |
| Genentech USA, INC. | $22.01 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $17.99 | 2021 | |
| Sun Pharmaceutical Industries INC. | $17.86 | 2021 | |
| Incyte Corporation | $17.37 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.80 | 2023 | Ycanth |
| Organogenesis INC. | $15.06 | 2021 | |
| Tactile Systems Technology INC | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caedran Peete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.